TY - JOUR
T1 - Neurotriphic factor in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy
AU - Caggiula, Marcella
AU - Batocchi, Anna Paola
AU - Frisullo, Giovanni
AU - Angelucci, Francesco
AU - Patanella, Agata Katia
AU - Sancricca, Cristina
AU - Nociti, Viviana
AU - Tonali, Pietro Attilio
AU - Mirabella, Massimiliano
PY - 2006
Y1 - 2006
N2 - Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy
AB - Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy
KW - interferon beta
KW - multiple sclerosis
KW - neurotrophic factors
KW - interferon beta
KW - multiple sclerosis
KW - neurotrophic factors
UR - http://hdl.handle.net/10807/19647
M3 - Article
SN - 1521-6616
SP - 77
EP - 82
JO - Clinical Immunology
JF - Clinical Immunology
ER -